Survival Status and Predictors of Mortality among Multidrug-Resistant Tuberculosis Patients in Saint Peter’s Specialized Hospital, Addis Ababa, Ethiopia

Table 3

Comorbidities among MDR-TB patients in SPSH, 2020 (n = 484).

Variables		Frequency	Percent (%)
HIV coinfection	Yes	96	19.8
	No	388	80.2
ART regimen (n = 95)	TDF-3TC-EFV	92	96.8
	AZT-3TC-EFV	3	3.2
CD4 count (n = 96)	Median CD4 count in cells/mm^3 (IQR)	163.5 (129.75,197.75)
Anemia	Yes	133	27.5
	No	351	72.5
	Median (IQR)	13.4 (12.2, 14.5)
Comorbidities (other than HIV)	Yes	49	10.1
	No	435	89.9
Types of comorbidities (other than HIV) (n = 49)	Diabetes	19	38.8
	Cardiac disease	18	36.8
	Hypertension	8	16.3
	Asthma	3	6.1
	Renal disease	1	2.0

TDF-3TC-EFV: tenofovir disoproxil fumarate-lamivudine-efavirenz, AZT-3TC-EFV: azidothymidine-lamivudine-efavirenz, IQR: interquartile range.